mail
versión imprimible
 
 

4th Annual Chronic Kidney Disease Drug Development Summit (CKD)

Evvnt Promotion / evvnt
-
01.03.2022 - 03.03.2022  Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 08:00 - 17:00
 
Temas de la conferencia
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
Organizador profesional (PCO)
Hanson Wade
Observaciones
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.
 

Información e inscripción:

https://go.evvnt.com/915880-2?pid=4832
Mr. Jessica Durston
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
USD 2099.0 - USD 4996.0
Los participantes esperaban
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Alumni Club Medizinische Universität WienAnästhesie in Entwicklungsländern e. V.Ärzte der WeltCenter of ExcellenceÖsterreichische Gesellschaft für Public HealthAGEM - Arbeitsgemeinschaft Ethnologie und MedizinAMREF - African Medical and Research FoundationEuropean Health Forum Gastein